Patents

8. Antisense oligonucleotides that bind to exon 51 of human dystrophin pre-mRNA.

Inventors: Toshifumi Yokota and Yusuke Echigoya* (2024) US Patent number

11891603. Date of Filing: July 20, 2018 – licensed to Avidity Biosciences 

7. DG9 Peptide-conjugated Splice-Modulating Therapies for the Treatment of Duchenne Muscular Dystrophy and Spinal Muscular Atrophy. Inventors:  Toshifumi Yokota, Rika Maruyama*, Hong Moulton (2022) U.S. Provisional Patent Application Serial No. 63/303,577. Date of Filing: January 27, 2022/ International Patent Application Serial No. PCT/CA2023/050096. Date of Filing: January 26, 2023. 

6. Preferential Knockdown of the Mutant Transcript ACVR1R206H and

Inhibition of Osteogenic Differentiation Using Allele-Selective LNA Gapmers for the

Treatment of Fibrodysplasia Ossificans Progressiva. Inventors:  Toshifumi Yokota, Rika Maruyama* (2021) U.S. Provisional Patent Application Serial No. 63/285,547. Date of Filing: December 3, 2021, International Application No. PCT/CA2022/051756. Date of Filing: December 1, 2022

5. Antisense Oligonucleotides for Exon Skipping. Inventors:  Toshifumi Yokota, Joshua Lee*, Rika Maruyama* (2019) U.S. Provisional Patent Application Serial No. 62/911,409. Date of Filing: October 7, 2019 

4. Exons 45-55 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene. Inventors:  Toshifumi Yokota, Yusuke Echigoya*, and Kenji Rowel Lim*. The United States Provisional Patent Application Serial No. 62/871,797. Date of Filing:  July 9, 2019, International application No. PCT/CA2020/050948. Date of Filing: July 9, 2020.– licensed to Avidity Biosciences

3. Antisense Oligonucleotides to Treat Patients with Dysferlin Deficiency. Inventors:  Toshifumi Yokota, Joshua Lee* (2018) U.S. Provisional Patent Application Serial No. 62/741,682. Date of Filing: October 5, 2018

2. Gapmers and Methods of Using the Same for Treatment of Muscular Dystrophy. Inventors:  Toshifumi Yokota, Rika Maruyama*, Yusuke Echigoya*, Yi-Wen Chen (2017) US Patent Number 11,518,955. Date of Filing: September 19, 2018

1. Antisense Oligonucleotide. Inventors:  Toshifumi Yokota and Yusuke Echigoya* (2017) UK patent application No GB 1711809.2. Date of Filing: July 21, 2017. International Application No. PCT/CA2018/050881. Date of Filing: July 21, 2018. – licensed to Pepgen Corporation Ltd. (2017-2020), Avidity Biosciences (2020-)

Last Updated: 7 June, 2024